{"url_path":"/sec/tovx/8-k/2026-06-05/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-070966-index.html","accession_number":"0001104659-26-070966","cik":"0000894158","ticker":"TOVX","issuer_name":"Theriva Biologics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/894158/0001104659-26-070966-index.html","primary_entity_key":"0000894158","primary_entity_name":"Theriva Biologics, Inc."},"word_count":320,"has_tables":true,"body_markdown":"false\n0000894158\n\n0000894158\n\n2026-06-05\n2026-06-05\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n \n\n**Pursuant to Section 13 or 15(d)**\n\n**of the Securities Exchange Act of 1934**\n\n  \n\n**Date of Report (Date of earliest event\nreported): June 5, 2026**\n\n \n\n**THERIVA BIOLOGICS, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Nevada**\n \n**001-12584**\n \n**13-3808303**\n\n(State or other jurisdiction of\n\nincorporation)\n \n(Commission File No.)\n \n(IRS Employer Identification\n\nNo.)\n\n \n\n**9605 Medical Center Drive, Suite 270**\n\n**Rockville, Maryland 20850**\n\n(Address of principal executive offices and zip\ncode)\n\n \n\n**(301) 417-4364**\n\nRegistrant’s telephone number, including\narea code\n\n \n\n**N/A**\n\n(Former name or former address, if changed since\nlast report)\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General\nInstruction A.2. below):\n\n \n\n \n¨\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n \n\n \n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n \n\n \n¨\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n \n\n \n¨\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\n**Title of each class**\n**Trading Symbol(s)**\n**Name\nof each exchange on which\nregistered**\n\nCommon stock, par value $0.001 per share\nTOVX\nNYSE American\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2\nof the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).\n\n \n\nEmerging growth company ¨\n\n \n\nIf an emerging growth company, indicate by checkmark\nif the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards\nprovided pursuant to Section 13(a) of the Exchange Act. ¨"}